Tevogen Bio Holdings Inc. (TVGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tevogen Bio Holdings Inc. on July 10, 2025. The report discloses "Other Events" (Item 8.01) related to restricted stock award grants approved by the Board of Directors on June 27, 2025.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only quantitative data disclosed relates to capital structure:
- Total Common Stock Outstanding: 193,693,433 shares as of July 10, 2025.
- Stock Class: Common Stock, par value $0.0001 per share (Trading Symbol: TVGN).
- Warrants: Warrants exercisable for one share of Common Stock for $11.50 per share (Trading Symbol: TVGNW).
Material Changes
The primary material change reported is the increase in outstanding shares due to new restricted stock awards. Specifically, 8,000,000 shares of restricted stock were granted to Dr. Ryan Saadi, the Chief Executive Officer and Chairperson. Additional grants were made to other grantees, though specific quantities for other individuals are not detailed in this text.
Management Commentary and Vesting Terms
Management has established specific vesting schedules for the new awards:
- Dr. Ryan Saadi: Shares vest in four equal annual installments beginning on the seventh anniversary of the grant date.
- Other Grantees: Shares vest in three equal annual installments beginning on the fifth anniversary of the grant date.
- Conditions: Vesting is subject to continuous service through the vesting date. Shares automatically vest in full in the event of termination due to death or disability.
- Restrictions: Shares may not be sold, assigned, transferred, pledged, or encumbered prior to vesting and are subject to automatic forfeit if conditions are not met.
Investor Verification Checklist
- Verify the total number of outstanding shares (193,693,433) against the company's latest 10-Q or 10-K filings to confirm the impact of these grants on dilution.
- Review the specific vesting schedules (7-year and 5-year cliffs) to assess long-term executive retention incentives.
- Confirm the total number of shares granted to "other grantees" to calculate the full dilutive impact of the June 27, 2025 board approval.
- Check for any subsequent filings regarding the exercise of warrants (TVGNW) given the $11.50 strike price relative to current market conditions.